{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:06:22Z","timestamp":1781888782322,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,19]]},"DOI":"10.7759\/cureus.82591","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T15:43:41Z","timestamp":1745077421000},"source":"Crossref","is-referenced-by-count":1,"title":["Topical Tacrolimus in the Management of High-Risk Keratoplasty: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Abdulmajeed","family":"Al Khathami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruba A","family":"Alamri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem A","family":"Garah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan S","family":"Alsamli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nourah B","family":"Alsheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar  B","family":"Alsheikh Alshahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazeed S","family":"AlHoshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M","family":"Alaklabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaima A","family":"Benyh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman","family":"Alamri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2008.402","article-title":"Mycophenolate mofetil (MMF) following penetrating high-risk keratoplasty: long-term results of a prospective, randomised, multicentre study","volume":"23","author":"Birnbaum F","year":"2009","unstructured":"Birnbaum F, Mayweg S, Reis A, et al.. Mycophenolate mofetil (MMF) following penetrating high-risk keratoplasty: long-term results of a prospective, randomised, multicentre study. Eye (Lond). 2009, 23:2063-70. 10.1038\/eye.2008.402","journal-title":"Eye (Lond)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.1995.99","article-title":"Systemic cyclosporine in high-risk keratoplasty: long-term results","volume":"9 ( Pt 4)","author":"Hill JC","year":"1995","unstructured":"Hill JC. Systemic cyclosporine in high-risk keratoplasty: long-term results. Eye (Lond). 1995, 9 ( Pt 4):422-8. 10.1038\/eye.1995.99","journal-title":"Eye (Lond)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-022-02318-w","article-title":"Topical administration of tacrolimus and corticosteroids in tapering doses is effective in preventing immune rejection\u00a0in high-risk keratoplasty: a 5-year follow-up study","volume":"22","author":"Qi X","year":"2022","unstructured":"Qi X, Wang L, Zhang X, Liu M, Gao H. Topical administration of tacrolimus and corticosteroids in tapering doses is effective in preventing immune rejection\u00a0in high-risk keratoplasty: a 5-year follow-up study. BMC Ophthalmol. 2022, 22:101. 10.1186\/s12886-022-02318-w","journal-title":"BMC Ophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2004.00006.x","article-title":"Topical FK506 as immunoprophylaxis after allogeneic penetrating normal-risk keratoplasty: a randomized clinical pilot study","volume":"18","author":"Reinhard T","year":"2005","unstructured":"Reinhard T, Mayweg S, Reis A, Sundmacher R. Topical FK506 as immunoprophylaxis after allogeneic penetrating normal-risk keratoplasty: a randomized clinical pilot study. Transpl Int. 2005, 18:193-7. 10.1111\/j.1432-2277.2004.00006.x","journal-title":"Transpl Int"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e3182a2c937","article-title":"Keratoplasty postoperative treatment update","volume":"32 Suppl 1","author":"Shimmura-Tomita M","year":"2013","unstructured":"Shimmura-Tomita M, Shimmura S, Satake Y, Shimazaki-Den S, Omoto M, Tsubota K, Shimazaki J. Keratoplasty postoperative treatment update. Cornea. 2013, 32 Suppl 1:S60-4. 10.1097\/ICO.0b013e3182a2c937","journal-title":"Cornea"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40135-017-0119-2","article-title":"Update on the management of high-risk penetrating keratoplasty","volume":"5","author":"Jabbehdari S","year":"2017","unstructured":"Jabbehdari S, Rafii AB, Yazdanpanah G, Hamrah P, Holland EJ, Djalilian AR. Update on the management of high-risk penetrating keratoplasty. Curr Ophthalmol Rep. 2017, 5:38-48. 10.1007\/s40135-017-0119-2","journal-title":"Curr Ophthalmol Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-003-0724-7","article-title":"Synergistic antiherpetic effect of acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease: first results of a randomised pilot study","volume":"241","author":"Mayer K","year":"2003","unstructured":"Mayer K, Reinhard T, Reis A, Voiculescu A, Sundmacher R. Synergistic antiherpetic effect of acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease: first results of a randomised pilot study. Graefes Arch Clin Exp Ophthalmol. 2003, 241:1051-4. 10.1007\/s00417-003-0724-7","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e3181606086","article-title":"Long-term use of topical tacrolimus (FK506) in high-risk penetrating keratoplasty","volume":"27","author":"Dhaliwal JS","year":"2008","unstructured":"Dhaliwal JS, Mason BF, Kaufman SC. Long-term use of topical tacrolimus (FK506) in high-risk penetrating keratoplasty. Cornea. 2008, 27:488-93. 10.1097\/ICO.0b013e3181606086","journal-title":"Cornea"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-6420(01)00759-x","article-title":"Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts","volume":"1","author":"Sloper CM","year":"2001","unstructured":"Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts. Ophthalmology. 2001, 1:1838-44. 10.1016\/s0161-6420(01)00759-x","journal-title":"Ophthalmology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2005.00126.x","article-title":"Systemic mycophenolate mofetil avoids immune reactions in penetrating high-risk keratoplasty: preliminary results of an ongoing prospectively randomized multicentre study","volume":"18","author":"Reinhard T","year":"2005","unstructured":"Reinhard T, Mayweg S, Sokolovska Y, et al.. Systemic mycophenolate mofetil avoids immune reactions in penetrating high-risk keratoplasty: preliminary results of an ongoing prospectively randomized multicentre study. Transpl Int. 2005, 18:703-8. 10.1111\/j.1432-2277.2005.00126.x","journal-title":"Transpl Int"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/11206721231172236","article-title":"Topical tacrolimus in high-risk corneal transplants","volume":"34","author":"Bernardes L","year":"2024","unstructured":"Bernardes L, Gil J, Costa E, Tavares C, Rosa A, Quadrado MJ, Murta J. Topical tacrolimus in high-risk corneal transplants. Eur J Ophthalmol. 2024, 34:140-5. 10.1177\/11206721231172236","journal-title":"Eur J Ophthalmol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2006.097428","article-title":"Tacrolimus immunosuppression in high-risk corneal grafts","volume":"91","author":"Joseph A","year":"2007","unstructured":"Joseph A, Raj D, Shanmuganathan V, Powell RJ, Dua HS. Tacrolimus immunosuppression in high-risk corneal grafts. Br J Ophthalmol. 2007, 91:51-5. 10.1136\/bjo.2006.097428","journal-title":"Br J Ophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.18502\/jovr.v14i4.5437","article-title":"Topical tacrolimus as an adjunct to conventional therapy for stromal herpetic keratitis: a randomized clinical trial","volume":"14","author":"Akbari M","year":"2019","unstructured":"Akbari M, Soltani Moghadam R, Elmi R, Nosrati A, Taghiabadi E, Aghdami N. Topical tacrolimus as an adjunct to conventional therapy for stromal herpetic keratitis: a randomized clinical trial. J Ophthalmic Vis Res. 2019, 14:400-11. 10.18502\/jovr.v14i4.5437","journal-title":"J Ophthalmic Vis Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-019-0717-3","article-title":"Observation of topical tacrolimus on high-risk penetrating keratoplasty patients: a randomized clinical trial study","volume":"34","author":"Zhai LY","year":"2020","unstructured":"Zhai LY, Zhang XR, Liu H, Ma Y, Xu HC. Observation of topical tacrolimus on high-risk penetrating keratoplasty patients: a randomized clinical trial study. Eye (Lond). 2020, 34:1600-7. 10.1038\/s41433-019-0717-3","journal-title":"Eye (Lond)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019050546","article-title":"Comparison of the efficacy and safety of tacrolimus and low-dose corticosteroid with high-dose corticosteroid for minimal change nephrotic syndrome in adults","volume":"32","author":"Chin HJ","year":"2021","unstructured":"Chin HJ, Chae DW, Kim YC, et al.. Comparison of the efficacy and safety of tacrolimus and low-dose corticosteroid with high-dose corticosteroid for minimal change nephrotic syndrome in adults. J Am Soc Nephrol. 2021, 32:199-210. 10.1681\/ASN.2019050546","journal-title":"J Am Soc Nephrol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-020-01375-z","article-title":"Topical 0.03% tacrolimus versus systemic mycophenolate mofetil as adjuncts to systemic corticosteroids for preventing graft rejection after repeat keratoplasty: one-year results of a randomized clinical trial","volume":"35","author":"Faramarzi A","year":"2021","unstructured":"Faramarzi A, Abbasi H, Feizi S, et al.. Topical 0.03% tacrolimus versus systemic mycophenolate mofetil as adjuncts to systemic corticosteroids for preventing graft rejection after repeat keratoplasty: one-year results of a randomized clinical trial. Eye (Lond). 2021, 35:2879-88. 10.1038\/s41433-020-01375-z","journal-title":"Eye (Lond)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.02.044","article-title":"A clinical trial comparing the safety and efficacy of topical tacrolimus versus methylprednisolone in ocular graft-versus-host disease","volume":"123","author":"Abud TB","year":"2016","unstructured":"Abud TB, Amparo F, Saboo US, et al.. A clinical trial comparing the safety and efficacy of topical tacrolimus versus methylprednisolone in ocular graft-versus-host disease. Ophthalmology. 2016, 123:1449-57. 10.1016\/j.ophtha.2016.02.044","journal-title":"Ophthalmology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000001408","article-title":"Topical tacrolimus as adjuvant therapy to corticosteroids in acute endothelial graft rejection after penetrating keratoplasty: a randomized controlled trial","volume":"37","author":"Hashemian MN","year":"2018","unstructured":"Hashemian MN, Latifi G, Ghaffari R, et al.. Topical tacrolimus as adjuvant therapy to corticosteroids in acute endothelial graft rejection after penetrating keratoplasty: a randomized controlled trial. Cornea. 2018, 37:307-12. 10.1097\/ICO.0000000000001408","journal-title":"Cornea"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000000258","article-title":"Efficacy and safety of systemic tacrolimus in high-risk penetrating keratoplasty after graft failure with systemic cyclosporine","volume":"33","author":"Yamazoe K","year":"2014","unstructured":"Yamazoe K, Yamazoe K, Yamaguchi T, Omoto M, Shimazaki J. Efficacy and safety of systemic tacrolimus in high-risk penetrating keratoplasty after graft failure with systemic cyclosporine. Cornea. 2014, 33:1157-63. 10.1097\/ICO.0000000000000258","journal-title":"Cornea"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2013-303639","article-title":"Topical 0.03% tacrolimus preventing rejection in high-risk corneal transplantation: a cohort study","volume":"97","author":"Magalhaes OA","year":"2013","unstructured":"Magalhaes OA, Marinho DR, Kwitko S. Topical 0.03% tacrolimus preventing rejection in high-risk corneal transplantation: a cohort study. Br J Ophthalmol. 2013, 97:1395-8. 10.1136\/bjophthalmol-2013-303639","journal-title":"Br J Ophthalmol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/359923-topical-tacrolimus-in-the-management-of-high-risk-keratoplasty-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T15:43:42Z","timestamp":1745077422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/359923-topical-tacrolimus-in-the-management-of-high-risk-keratoplasty-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,19]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.82591","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,19]]}}}